companies & Investments

A track record of innovation
Accelerating mental healthcare solutions

A track record of innovation
Accelerating mental healthcare solutions

ATAI Life Sciences is dedicated to bringing innovation to mental healthcare, a field that has seen little progress since the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the 1980s and 1990s, respectively.

Want to learn more about our companies and investments?  Check them out below.

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.


developing ibogaine and noribogaine for the treatment of opioid use disorders


leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.

GABA Therapeutics

develops GRX-917 — a deuterated version of etifoxine — for anxiety.

EntheogeniX Biosciences

leverages the power of AI and computational biophysics to design the next generation of mental health drugs


preventing post-concussion injury and mental health complications by novel nose-to-brain drug delivery of NAC

Introspect DTx

developing personalized digital tools to enhance psychedelics-assisted psychotherapy


developing novel therapeutics for addiction and depression

Viridia Life Sciences

exploring the potential of rapid acting psychedelics for scalable mental healthcare


leveraging the power of MDMA to deliver next generation PTSD treatments